Syensqo (SYENS) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Welcomed shareholders to the first meeting as an independent company, celebrating the journey to independence and key milestones like the Euronext listing.
Expressed gratitude to shareholders, founding families, and new investors for their support and trust.
CEO Dr. Ilham Kadri opened the meeting, emphasizing the company's mission to explore, create, and advance humanity through innovation and sustainability.
Highlighted the company's unique value proposition, combining legacy with a startup mindset and a purpose-driven approach.
Financial performance review
Achieved 2023 net sales of EUR 6.8 billion and EBITDA of EUR 1.6 billion with a 23.7% margin; operating cash flow reached EUR 1.3 billion and cash conversion was 85%.
Composite materials grew 15% due to strong aviation demand.
Q1 2024 net sales were EUR 1.62 billion, EBITDA EUR 363 million, and cash conversion 89%.
Maintained a strong balance sheet with a leverage ratio of 1x, net debt reduced to EUR 1.7 billion, and investment-grade credit ratings.
Top quartile performance among direct peers in sales, EBITDA growth, and ROCE improvement over the past two years.
Board and executive committee updates
Introduced CFO Christopher Davis, who joined in September and contributed to roadshows and financial strategy.
60% of the Board of Directors and 30% of the Executive Committee are women, with a goal of gender parity in management by 2033.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025